Related Tags >> FDA pharmaceuticals Regulators Shire Pharmaceuticals

ADHD News

Most Popular ADHD Story

FDA approves Lilly's ADHD drug Strattera

May 8, 2008 — 6:59am ET

Eli Lilly has won FDA approval of Strattera, a therapy designed to treat ADHD. Lilly says this is the first regulatory win for a non-stimulant ADHD drug in a market dominated by two... Read more...

ADHD Press Releases

FDA Issues Safety Communication about an Ongoing Review of Stimulant Medications Used in Children with ADHD
PRESS RELEASE: AHRQ and FDA to Collaborate in Largest Study Ever of Possible Heart Risks With ADHD Medications
FDA STATEMENT: AHRQ and FDA to Collaborate in Largest Study Ever of Possible Heart Risks With ADHD Medications

Latest Headlines

FDA approves Lilly's ADHD drug Strattera
May 8, 2008
Blogster sees lessons in FDA approvable letters
February 21, 2008
Cortex drops bid to test drug for ADHD
October 11, 2007
Noven garners $25M payday on sales milestone
July 31, 2007
Cortex gets green light to resume Alzheimer's trials
July 17, 2007
Pfizer inks genetic license with Genizon
January 15, 2007
ALSO NOTED: Shire drug gets second approvable letter; Galapagos acquires ProStrakan sub; FDA asks Allergan for more data; and m
December 21, 2006
FDA demands tougher warnings on stimulants
August 21, 2006
Cephalon shares tank after Sparlon rejection
August 9, 2006
Cortex shares plunge on CX717 failure
June 21, 2006
SPOTLIGHT: CDC estimates reignite ADHD controversy
May 24, 2006
Cephalon provides update on Sparlon
April 18, 2006
FDA approves Daytrana ADHD patch
April 6, 2006
FDA committee votes against ADHD "black box"
March 22, 2006
FDA staffers question safety of Sparlon for ADHD
March 21, 2006
FDA panel wants 'black box' on ADHD drugs
February 9, 2006
FDA troubled by deaths among ADHD patients
February 8, 2006
SPOTLIGHT: FDA committee to review ADHD risks
February 1, 2006
FDA staffer reverses course on ADHD patch
December 1, 2005
FDA: Cylert risks outweigh benefits
October 23, 2005

Paid Research Reports

More Research Reports >>